Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07641504 · ClinicalTrials.gov registry record · Phase 2
A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Chronic Low Back Pain
A Phase 2 study, sponsored by Eli Lilly and Company.
- Not yet
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
NCT07641504 is a Phase 2 study that has not yet begun recruiting, run by Eli Lilly and Company. The registered enrollment target is 150 participants.
The verdict
NCT07641504, a Phase 2 study, has not yet begun recruiting, sponsored by Eli Lilly and Company.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
Study Summary
The main purpose of this study is to test the safety and efficacy of study drug for the treatment of chronic low back pain (CLBP). This trial is part of the chronic pain master protocol H0P-MC-CPMP (NCT05986292), which is a protocol to accelerate the development of new treatments for chronic pain.
Interventions
- DRUG Placebo
- DRUG LY4065967
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2026-07 |
| Est. Completion | 2027-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07641504
The ClinicalTrials.gov registry entry for NCT07641504 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07641504 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07641504 about?
NCT07641504 is a clinical study titled "A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Chronic Low Back Pain". The main purpose of this study is to test the safety and efficacy of study drug for the treatment of chronic low back pain (CLBP). This trial is part of the chronic pain master protocol H0P-MC-CPMP (NCT05986292), which is a protocol to accelerate the development of new treatments for chronic pain.
What is the current status of trial NCT07641504?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2026-07. Estimated completion is 2027-04.
What interventions are being tested in trial NCT07641504?
The interventions under investigation include: Placebo (DRUG), LY4065967 (DRUG).
Who is sponsoring clinical trial NCT07641504?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.